Proposal to list interventional radiology medical devices supplied by Becton Dickinson Limited
PHARMAC is seeking feedback on a proposal to list a range of interventional radiology products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020 through a provisional agreement with Becton Dickinson Limited.
Consultation closes at 4pm on Thursday, 28 November 2019 and feedback can be emailed to firstname.lastname@example.org.
What would the effect be?
From 1 February 2020, BD’s range of interventional radiology products would fall under a proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate. The Agreement provides national consistency for these devices as the terms and conditions, including price, stated in the Agreement apply to all DHB purchases from the date of listing on the Pharmaceutical Schedule.
The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of interventional radiology products.
This Agreement would supersede any existing DHB contract with the supplier for the devices listed in the Schedule 1 of the Agreement. Any device listed in the PHARMAC Agreement and purchased by a DHB would be at the terms and conditions, including price, stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
BD would provide appropriate training and education services that would be tailored to the individual needs of the DHBs, in formats and at times as required by DHBs.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- DHB Staff
- Interventional radiology staff
- Procurement officers and supply chain personnel
- Suppliers and Wholesalers
About interventional radiology products
Interventional radiology refers to a range of minimally invasive alternatives to surgery to diagnose and treat a variety of conditions in nearly every organ system, that are performed using radiologic imaging guidance to precisely target the intervention. The procedures are performed using catheters inserted via either radial or femoral arteries or veins.
The imaging modalities used include general radiography including fluoroscopy, angiography, ultrasound, computed tomography, and magnetic resonance imaging.
Interventional radiology in some form is performed in all hospitals across New Zealand.
Why we’re proposing this
In September 2017, PHARMAC issued a Request for Proposals (RFP) for interventional radiology consumable products.
The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
PHARMAC has been working with suppliers to seek provisional agreements and this is the latest proposal to arise from those processes. This is the final agreement for the interventional radiology category.
Details about our proposal
This proposal would result in 19 medical devices from the Jamshidi range of needles used in interventional radiology procedures being listed on the Pharmaceutical Schedule.
A full product list with pricing has been made available to appropriate DHB personnel.
To provide feedback
Send us an email: email@example.com by 4pm on Thursday, 28 November 2019.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.